Evidence map›Paper›PMID 33859940›Full record

ArticleFrontiers in oncology2021

Transcriptome Analysis of Ivosidenib-Mediated Inhibitory Functions on Non-Small Cell Lung Cancer.

Juan Wu, Ru Chen, Huiqing Shen, Ting Yan, Yu Qian, Yaping Zhang, Zhuoya Huang, Pengzhou Kong, Min Pang, Xinri Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Juan WuDepartment of Respiratory and Critical Care Medicine, The First Hospital, Shanxi Medical University, Taiyuan, China.
Ru ChenDepartment of Respiratory and Critical Care Medicine, The First Hospital, Shanxi Medical University, Taiyuan, China.
Huiqing ShenDepartment of Respiratory and Critical Care Medicine, The First Hospital, Shanxi Medical University, Taiyuan, China.
Ting YanDepartment of Pathology & Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, China.
Yu QianDepartment of Pathology & Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, China.
Yaping ZhangDepartment of Respiratory and Critical Care Medicine, The First Hospital, Shanxi Medical University, Taiyuan, China.
Zhuoya HuangDepartment of Respiratory and Critical Care Medicine, The First Hospital, Shanxi Medical University, Taiyuan, China.
Pengzhou KongDepartment of Pathology & Shanxi Key Laboratory of Carcinogenesis and Translational Research on Esophageal Cancer, Shanxi Medical University, Taiyuan, China.
Min PangDepartment of Respiratory and Critical Care Medicine, The First Hospital, Shanxi Medical University, Taiyuan, China.
Xinri ZhangDepartment of Respiratory and Critical Care Medicine, The First Hospital, Shanxi Medical University, Taiyuan, China.
First Hospital of Shanxi Medical University · CNShanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ivosidenib is an isocitrate dehydrogenase mutant inhibitor that the US Food and Drug Administration recently approved for the treatment of leukemia. Studies suggested that ivosidenib may inhibit the progression of non-small cell lung cancer (NSCLC). In the present study, we explored RNAs and their potential regulatory mechanisms by which ivosidenib treats NSCLC cells. We used MTT assays, Transwell assays, and flow cytometry to measure the anti-tumor effects of ivosidenib in NSCLC cells. We performed whole transcriptome sequencing to determine differentially expressed mRNAs (DE-mRNAs) and non-coding RNAs (ncRNA). We used GO and KEGG pathway enrichment analyses to identify the functions and potential mechanisms. According to miRNA target interactions, we constructed a competing endogenous network. Ivosidenib inhibited the proliferation, invasion, and migration of NSCLC cells and inhibited tumor growth

Indexed as

bioinformatic analysisceRNAivosidenibnon-small cell lung cancerRNA-seq

Identifiers

PMID33859940
PMCPMC8042334
OpenAlexW3151548249

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.